The enemy of knowledge is not ignorance, it’s the illusion of knowledge (Stephen Hawking)

It ain’t what you don’t know that gets you into trouble. It’s what you know for sure that just ain’t so (Mark Twain)

Invest with smart knowledge and objective odds

THE DAILY EDGE: 11 NOVEMBER 2020

US labour market recovery set to lose steam in the short term

(…) If the pace of employment gains experienced over the past three months can be sustained, the US would be back to its pre-COVID level of employment by September next year. However, there are reasons to think that this pace will not be sustained. For one, any further fiscal support is likely to be much less generous than in the spring. Meanwhile, daily new coronavirus cases are surpassing previous peaks. Against that backdrop, we expect softer employment growth in the months to come, with therapeutics or a vaccine possible tailwinds to jobs growth next year.

U.S. JOLTS: Job Opportunities Rate Holds Steady but Hiring Slips

(…) The job openings level rose 1.3% to 6.436 million, down 8.7% y/y. The job openings level in the construction sector fell 31.2% y/y but in manufacturing, it rose 3.4% y/y. It fell by 21.5% y/y in leisure & hospitality but rose 1.3% y/y in the professional & business service sector. In government, the number of job openings declined 3.6% y/y. (…)

In September, the level of hiring declined 1.4% to 5.871 million (-1.5% y/y) following a 0.8% August gain. (…)

fredgraph - 2020-11-11T061017.000

fredgraph - 2020-11-11T061106.373

The fact that there was not much change in the latest data from the federal Job Openings and Labor Turnover Survey (JOLTS) is a bad sign for this labor market recovery. The number of job openings didn’t really change from the month before. The quits rate, a sign of worker confidence, was also very similar to the prior month. For signs of a strong labor market recovery, both of these numbers need to rise. That is not what we are seeing.

Another concerning sign is that while layoffs went down in September, the outlook for jobless workers looking for a new job worsened. A measure of unemployment that more fully captures permanent unemployment— the ratio of unemployed workers to job openings — increased in September.

It’s hard to see any signs of backsliding, but there aren’t any signs of acceleration in the recovery either. Hiring isn’t speeding up, and, if job openings are any indication, it is unlikely to do so in the near term. In a labor market with 10 million fewer jobs than February, we need to see hiring moving at a faster clip to avoid lasting damage.

bar graph tightness of the labor market varied by unemployment metric

U.S. Covid-19 Cases Hit Fresh High Coronavirus cases continue to surge across much of the U.S. as hospitals in some states grapple with crowded intensive-care units.

The U.S. set another single-day record for coronavirus cases, as the total number of new infections topped 136,000, while hospitalizations due to Covid-19 were at their highest level since the pandemic began. (…)

Hospitalizations, up around 30% since the beginning of the month, reached 61,964 as of Tuesday, exceeding the previous high of 59,940 reached on April 15, according to the Covid Tracking Project. A summer surge also saw hospitalizations reach just shy of 60,000 in July.

Intensive-care units are also facing an upsurge in patients due to the pandemic, with 11,952 people in ICUs in the U.S. as of Tuesday, the highest number since May 7. (…)

0_All Key Metrics (42)

image

U.S. metropolitan areas are averaging a record 27.8 daily coronavirus cases per 100,000 people, according to U.S. Centers for Disease Control and Prevention data. Although rural areas are still worse on a per-capita basis, it’s clear that cities have been swept up in the pandemic again.

The surge has expanded from highly rural states in the Midwest and Rocky Mountain West to areas with bigger populations and more urban living. That has meant rising cases in and around Denver, Detroit and Chicago. Further to the east, the virus is mounting a comeback around Newark, New Jersey, and Boston. (…)

unnamed (99)

Source: WSJ

(…) The share of New York City residents who tested positive for the new coronavirus last week reached 2.31%, the highest percentage since June, according to city data. The daily positivity rate was 2.88% on Sunday, the data showed. (…) Hitting a 3% positivity rate on a seven-day average across the city could also trigger more restrictions, such as moving public schools to all-remote instruction and closing some businesses. (…)

New York state added nearly 4,000 Covid-19 cases on Monday, according to the governor’s office. The state’s daily positivity rate was 3.09%; the rate hasn’t hit 3% since May 26 and the state hasn’t seen this case load since May 1. On Monday, there were 32 deaths from the virus in New York. (…)

  • Israel was first to impose national restrictions, entering a month of lockdown from 18 September. Ireland followed, beginning a six-week period of national lockdown on 21 October. The renewed lockdowns in these two countries have proved extremely effective in bringing down the number of identified cases of COVID-19. Fathom Consulting)

image

image

image
Banks in Europe Face Potential $1.7 Trillion Covid-19 Cliff European banks say they are doing just fine during the coronavirus pandemic. But regulators and bank executives are concerned about the elephant in the room: a wave of bad loans that could overwhelm lenders when government rescue packages end.

(…) The European Central Bank said bad loans in the eurozone could soar as high as €1.4 trillion, equivalent to $1.7 trillion, if the economies fall even more than expected, a scenario the central bank said is severe but plausible. That amount would be more than during the aftermath of the financial crisis.

The concern is that banks could run out of capital if they are suddenly overwhelmed by defaults, needing state support or even failing. What isn’t clear right now is how quickly those defaults could pile up, or if state programs might cushion banks’ losses for years to come. (…)

In Italy—where banks are still trying to deal with old bad-debt portfolios—over 25% of loans to businesses and 15% to households, totaling around €300 billion, were put under payment holidays, according to Marco Troiano, deputy head of the banks team at the ratings company Scope Ratings. (…)

In Portugal, where companies and the government are highly indebted, loan moratoriums to businesses covered almost a third of the total, according to the country’s central bank. Over half of the credit to companies in the hospitality and restaurant sectors are under the program. (…)

Part of the reason for the rosy picture from banks comes down to accounting rules. Banks can typically count a loan as performing until there is actual deterioration, such as missed interest payments or a company going bankrupt.

Andrea Enria, the head of the ECB’s supervision arm, said some banks are being optimists and waiting until there is concrete evidence a customer is going bankrupt. (…)

Borrowers still taking payment holidays on $90bn of loans at top US banks Total halved over third quarter but remains elevated, obscuring outlook for defaults
Ackman places new bet against corporate credit Billionaire says markets are once again complacent about the impact of pandemic

(…) “I hope we lose money on this next hedge,” Mr Ackman said. “We’re in a treacherous time generally and what’s fascinating is the same bet we put on eight months ago is available on the same terms as if there had never been a fire and on the probability that the world is going to be fine.” (…)

Cyclical Stocks Power Dow Industrials Higher

(…) The Dow has outperformed the technology-heavy Nasdaq by 6.74 percentage points this week, the largest two-day performance spread since March 2001. It rose 262.95 points, or 0.9%, to 29420.92 on Tuesday, its third-highest close in history. Boeing, Chevron and 3M were among the biggest gainers.

The Nasdaq Composite, meanwhile, fell 159.53 points, or 1.4%, to 11553.86, with the big technology stocks that have powered much of this year’s stock rally pulling back for a second consecutive session. The S&P 500 edged down 4.97 points, or 0.1%, to 3545.53. (…)

unnamed (14)

unnamed (98)

Buy-losers-and-sell-winners hits historic proportions

(…) The two periods with dispersions as great as they are now both led to extended periods of smaller stocks doing better than larger ones.

The same pattern holds true for value versus growth stocks. By the time dispersion among the factors reached the current level, value stocks were about to embark on multiple years with massive outperformance relative to growth.

Investors have been looking for a turn in these relationships for years, and yet in most respects, they just keep getting more extreme. It seems like Monday’s shock, building on the massive differences in positioning for most of this year, is enough to equate to some of the most notable changes in 75 years, and that has been a very good relative sign for small and value stocks.

Out of all the major indexes, none are benefitting from the positive vaccine developments more than the Russell 2000 index of small-capitalization stocks.

Even without Monday’s massive rally, it has performed well enough that its medium-term trend has jumped well above its long-term one, thanks to a kick-off surge in early October. Respected technician Helene Meisler noted that the 50-day average of the index has moved the most above its 200-day average since 2017.

Russell 2000 spread between 50 and 200 day average

While there have been wider spreads between the two trend measures, by the time it reached 8%, it has been a good sign for the index.

Returns were okay over the short- to medium-term but really shined over the next year. There were no losses out of the 11 signals, and the risk/reward was impressively skewed to the upside.

Goldman’s bull case:

S&P 500 index: We lift our year-end 2020 target to 3700 (+4%) consistent with our previously published fair value estimate of the market under a divided Congress scenario. Our prior target was 3600. We forecast S&P 500 will climb by 16% to 4300 at year-end 2021 and gain 7% to reach 4600 by the end of 2022. The market is actually less dependent on the performance of a few mega-cap stocks than many investors perceive.

Stronger-than-expected 3Q results lead us to raise our S&P EPS forecasts to $175 in 2021 (from $170) and to $195 in 2022 (from $188) reflecting growth of 29% and 12%, respectively. For comparison purposes, our top-down 2021 EPS forecast is 4% above the bottom-up consensus expectation of $168 and 13% above the median consensus top-down forecast of $155.

image

Valuation: Falling equity risk premium supports a higher valuation for stocks. Our S&P 500 year-end 2020 target implies a forward P/E multiple of 21x. We project the multiple will expand to 22x by end 2021 and remain stable in 2022.

Note: The red lines above and below are mine. image

But GS rises to the valuation challenge:

Reconciling the signals of absolute vs. relative valuation is challenging. Stocks are highly valued on an absolute basis relative to history. The aggregate index trades above the 90th percentile on a variety of metrics including P/E, EV/sales, EV/EBITDA, Price/Book, and market cap/GDP. This suggests caution is warranted. However, the index and the median S&P 500 constituent are actually modestly undervalued on a relative basis compared with US Treasury yields and corporate bond yields, currently averaging at the 42nd percentile since 1976.

But why are interest rates so low again?

Rosenberg: Pfizer’s promising COVID-19 vaccine is a potential game changer for the economy and how to invest

(…) I had been in the camp of Dr. Anthony Fauci, where a vaccine was more of a late 2021 story with perhaps 60-per-cent efficacy. Now that timetable may well be moved up to no later than late in the first quarter and, at 90 per cent, there is no longer the fear that a take-up is going to be low.

The bottom line is that downside economic risks, which always have been tied to health risks, have subsided sharply. (…)

All that said, there are tailwinds for the equity market here, and the value stocks are still so cheap in relative and absolute terms that this trade could persist a while longer. But at this point, the Pfizer news has to go from success in a trial to something real and tangible. (…)

If the initial market reaction is correct, then we should be seeing the inoculations begin by the end of the first quarter of 2021. This is what is being priced in. That means no first-quarter U.S. GDP contraction and it means a likely second-quarter economic boom.

We shouldn’t be too dismissive of the timing. First, winter is coming and that means, absent a vaccine, the case counts, hospitalizations and fatalities are likely to get worse. Human nature is such that people will now be willing to be patient with the vaccine coming soon. As in, why screw this up? So this, along with thin U.S. stimulus spending, does complicate the economic backdrop for this quarter and perhaps into the first quarter of the new year. (…)

If people begin to see that life is going back to normal, we are talking about a US$700-billion hole in the consumer-services area of the economy (like airlines, rail, hotels, restaurants, retail, etc.) that will get filled, and likely rather quickly. This is a 3-per-cent boost to U.S. GDP right there, not including all the other multiplier effects from a speedier pace of job creation and generally increased economic confidence. (…)

China tech stocks tumble as regulators step up antitrust pressure Sector loses almost $254bn in value as banking watchdog focuses on fintech monopolies
Most Americans believe Joe Biden won. About 79% of those surveyed by Reuters/Ipsos, including almost six in 10 Republicans, backed the outcome, while 13% said the result is still undecided and 3% think Trump won. (Bloomberg)

THE DAILY EDGE: 10 NOVEMBER 2020

Pfizer Vaccine: What You Need to Know

(…) “It seems to be a proof of principle that we can make a vaccine, that it can make an immune response, that it does look safe in individuals that have been studied so far and that it actually works in the real world to protect against Covid,” said Dr. Buddy Creech, director of the Vanderbilt Vaccine Research Program in Nashville, Tenn., said in an interview. “That’s all you can hope for in any vaccine. And for it to have occurred this quickly and this rigorously is really encouraging.” (…)

The analysis took place too soon for researchers to figure how long the protection conferred by the vaccine will last; the data only looked how well the vaccine worked seven days after subjects got a second shot. (…) “Is this going to be a handful of months, like the flu vaccine? Is it going to be like measles or smallpox where it’s lifelong immunity?” It also is unclear whether the vaccine worked at protecting against severe Covid-19 disease. Nor is it clear whether the vaccine worked in all the different populations that would be in line to get one, including the elderly, children and various racial and ethnic groups. Pfizer and BioNTech are expected to release additional data later.

  • “The results are really quite good, I mean extraordinary,” said Dr. Anthony Fauci.
  • More than a dozen economies have inked supply deals with Pfizer and BioNTech for their vaccine. The duo expects to be able to produce 1.3 billion doses of their shot, enough for 650 million people, by the end of 2021. About 50 million doses are expected to be available this year. (Bloomberg)
  • The U.S. government has already purchased 100 million doses, with an option to buy another 500 million. That could theoretically cover America’s 255 million adults, and most of those under 18. (Axios)

France, Germany, Italy?…

Eli Lilly’s Covid-19 Antibody Drug Gets FDA Green Light Authorization of the drug addresses a hole in Covid-19 treatment, providing options for the infected before they require hospitalization

The U.S. Food and Drug Administration said Eli Lilly LLY -0.29% & Co.’s antibody drug should be used for patients ages 12 and up with mild to moderate Covid-19, based on a study showing it helped improve symptoms and kept many patients out of the hospital.

The FDA said the drug is authorized for patients at high risk of progressing to severe Covid-19, including people 65 and older, or who have certain chronic medical conditions. The drug shouldn’t be given to hospitalized patients, the FDA said, because it showed no clinical benefit in a study among such patients. (…)

Brazil Suspends Trials of Chinese Vaccine The clinical trials were halted following a ‘severe adverse event’

(…) Sinovac said in a statement Tuesday that it was still confident in the safety of the vaccine and that it was in contact with Butantan, which told the firm that it doesn’t believe the event is related to the vaccine. Sinovac spokesman Liu Peicheng said it hasn’t found any adverse cases in other ongoing trials for the vaccine. (…)

unnamed (95)Data: Our World in Data; Chart: Naema Ahmed/Axios

Small Business Optimism Remains Steady in October, but Owners’ Uncertainty Increased

The NFIB Optimism Index remained at 104.0 in October, unchanged from September and a historically high reading. Four of the 10 components improved, 5 declined, and 1 was unchanged. Although all of the data was collected prior to Election Day, a 6-point increase in the NFIB Uncertainty Index to 98 was likely driven by the election and uncertain conditions in future months due to the COVID-19 pandemic and possible government mandated shutdowns. The uncertainty reading was the highest reading since November 2016.

image

image

image

Small business owners uncertain of survival without new stimulus

The positive news about a possible coronavirus vaccine could prove to be a negative for many struggling small business owners, as economists worry that it could reduce the urgency for Congress to pass a new fiscal relief package.

A new survey from Goldman Sachs through its 10,000 Small Businesses program provided first to Axios finds that more than half of small business owners (52%) have stopped paying themselves in a bid to keep their businesses afloat and four in 10 (42%) already have begun laying off employees or cutting worker pay.

  • 33% have dipped into personal savings to stay operational.
  • 28% say the legislative uncertainty has caused them to consider closing their business.

Moving forward, 38% of those surveyed said they will have to lay off more employees or cut employee compensation and 20% said they will not be able to pay their commercial rent through the end of the year without additional help from Congress. (…)

unnamed (97)

China consumer price inflation hits lowest level in more than a decade Official data raise spectre of deflation in wake of Covid-19 pandemic

The consumer price index rose 0.5 per cent year-on-year in October, official data show, lower than economists’ expectations of 0.8 per cent. That compared to a 1.7 per cent rise in September and 2.4 per cent in August. (…)

Core CPI inflation, which excludes food and energy, was 0.5 per cent in October and has remained at that level — its lowest since 2010 — for several months. (…)

ANOTHER CHANGE IN LEADERSHIP?

Yesterday, stocks closed well off their best levels. DJIA +2.95%, S&P 500 +1.17%, NASDAQ -1.52%, S&P 600 +4.88%.

Energy and Financials won big from their bottom of the 2020 performance ranks. The potential vaccine could change the narrative away from “tech companies are the only growers during a pandemic” to a “back to normal, where’s growth at a reasonable price” market.

spy

rsp

unnamed (96)

Reproduced from Charles Schwab; Chart: Axios Visuals

  • The 30-company Dow was boosted by Disney, Boeing and Chevron, which each gained more than 11% on the day. The tech-heavy Nasdaq had its worst day since Oct. 30 and was led downward by companies like Netflix, which fell by around 9%, as well as Zoom and Peloton, which both declined by almost twice that much on the day.

  • Value and cyclical stocks outperformed growth and momentum stocks by the most in a single session since 2000 by some measures, according to FactSet. (Axios)

Not meaty enough: Beyond Meat shares fell by as much as 27% in after-hours trading after releasing underwhelming earnings that showed the company returning to a quarterly net loss and revenue that badly missed expectations. (CNBC)

U.S. vs. China in 5G: The Battle Isn’t Even Close China is leading the way in the size and consistency of its 5G network

China has more 5G subscribers than the U.S., not just in total but per capita. It has more 5G smartphones for sale, and at lower prices, and it has more-widespread 5G coverage. Connections in China are, on average, faster than in the U.S., too. (…)

Where China has a definite edge is in the nuts and bolts of 5G. By year’s end, China will have an estimated 690,000 5G base stations—boxes that blast 5G signals to consumers—up and running across the country, compared with 50,000 in the U.S., according to Handel Jones, chief executive of International Business Strategies Inc., a research firm. (…)

In China, 5G phones are less expensive, too: $458, on average, in the second quarter of this year, compared with $1,079 in the U.S., according to Canalys. (…)

The top-down approach has led to a more uniform version of 5G throughout the country, compared with the U.S., and more consistent speeds, says Wayne Lam, director of research at CCS Insight. “There’s a lot more central planning” behind China’s approach, Mr. Lam says.

The U.S., by contrast, has more-fragmented 5G coverage and uneven speeds. For example, while superfast 5G known as “millimeter wave” exists in a few crowded hot spots, like stadiums—and is not yet available to consumers in China—5G is slower everywhere else in the U.S.

(…) China’s 5G network covers only 8% of the population. In South Korea, by comparison, 5G covers 25% of the population, said Mr. Ding, who added that China’s 5G network is also slower than those of South Korea, Switzerland and other countries. (…)

“At present, China has built the world’s largest 5G network,” Mr. Ding said. However, he added, when compared with South Korea, Switzerland and a handful of other countries on the cutting edge of 5G, China still has room for improvement. (…)

Boeing Jets, Other U.S. Goods Worth $4 Billion Face EU Tariffs The European Union will impose tariffs on $3.99 billion of Boeing jets and other U.S. goods annually as part of a long-running trade dispute, the bloc’s trade chief said.
Silicon Valley Gets Another President Skeptical of Big Tech As a candidate, Joe Biden lambasted Facebook for what he considered failures to contain the spread of misinformation. His presidential election win puts him in a position to do something about it.
Amazon Faces New EU Antitrust Charges Amazon.com faces a fresh legal battle with the European Union, with the bloc set to file formal charges against the online retailer for alleged unfair business practices Tuesday, according to a person familiar with the matter.

Election latest. Attorney General William Barr authorized the DOJ to open probes into potential irregularities, while acknowledging there’s no conclusive evidence. His elections crime chief Richard Pilger quit in response, saying the move “abrogated the forty-year-old non-interference policy.” Joe Biden’s team threatened legal action if the White House doesn’t declare him the winner. (Bloomberg)

imagehttps://bit.ly/2020-Elections-Mehlman